|
|
|
| Effect of triptolide on human renal carcinoma A498 cells proliferation,migration and invasion |
| CAO Bo1 FU Gang2 WANG Xiao-min3 CHAI Chun-xiang1 ZHANG Zhao-guang4 CHEN Xue-xun5▲ |
1.Department of Emergency, Affiliated Hospital of Weifang Medical College, Shandong Province, Weifang 261041,China;
2.Department of Urinary Surgery, Weifang Yidu Central Hospital, Shandong Province, Qingzhou 262500, China;
3.Department of Pathology, Weifang Yidu Central Hospital, Shandong Province, Qingzhou 262500, China;
4.Department of Ultrasound, Affiliated Hospital of Weifang Medical College, Shandong Province, Weifang 261041, China;
5.Department of Nephrology, Affiliated Hospital of Weifang Medical College, Shandong Province, Weifang 261041,China |
|
|
|
|
Abstract ective To investigate the effect of triptolide on the proliferation, migration and invasion of human renal carcinoma A498 cells.Methods A498 cells exposed to different concentrations of triptolide.The concentrations of triptolide were 0, 200, and 400 nmol/L, which were defined as control group, low-dose group and high-dose group.Western Blot was used for testing the expressions of AKT, p-AKT, MTOR and p-MTOR in A498 cells, and the proliferation, migration and invasion were evaluated.Results The expressions of p-AKT and p-MTOR in the low-dose group and highdose group were lower than those in the control group, the expressions of p-AKT and p-MTOR in the high-dose group were lower than those in the low-dose group, and the differences were statistically significant (P＜0.05).The proliferation,migration and invasion ability of A498 cells in the low-dose group and high-dose group were lower than those of the control group, the proliferation, migration and invasion ability of A498 cells in the high-dose group were lower than those of the low-dose group, and the differences were statistically significant (P＜0.05).Conclusion Triptolide can inhibit the proliferation, migration and invasion of A498 cells by blocking the PI3K/AKT/mTOR signal pathway.
|
|
|
|
|
|
| [3] |
Kumar A，Kumari N，Gupta V.Renal cell carcinoma：molecular aspects[J].Indian J Clin Biochem，2018，33（3）：246-254.
|
| [1] |
Soleimani A，Rahmani F，Ferns GA，et al.Role of regulatory oncogenic or tumor suppressor miRNAs of PI3K/AKT signaling axis in the pathogenesis of colorectal cancer[J].Curr Pharm Des，2018，24（39）：4605-4610.
|
| [2] |
Errarte P，Larrinaga G.The role of cancer-associated fibroblasts in renal cell carcinoma an example of tumor modulation through tumor/non-tumor cell interactions[J].J Adv Res，2020，21（9）：103-108.
|
| [4] |
郭双双，张治业，王颖.PI3K/AKT/MTOR信号通路对肾癌A498细胞增殖、迁移及侵袭的影响研究[J].癌症进展，2017，15（12）：1412-1416.
|
| [5] |
潘理会，张平，李春辉.PI3K/AKT/mTOR信号传导通路在胃癌中的研究进展[J].承德医学院学报，2016，33（4）：324-327.
|
| [6] |
卢训西，国琳玮，李小光.P13K/AKT/mTOR 通路及其抑制剂在乳腺癌中的应用现状[J].中国癌症杂志，2020，30（2）：154-160.
|
| [7] |
Ediriweera MK，Tennekoon KH.Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer：Biological and therapeutic significance[J].Semin Cancer Biol，2019，59（11）：146-160.
|
| [8] |
Sun Z，Cao B.Protease-activated receptor 2 enhances renal cell carcinoma cell invasion and migration via PI3K/AKT signaling pathway[J].Exp Mol Pathol，2015，98（3）：382-389.
|
| [9] |
黄宇，马全鑫，凌云.雷公藤甲素抗肿瘤药理作用的研究进展[J].药物评价研究，2018，41（2）：328-333.
|
| [10] |
石金凤，罗尧尧，李佳鑫.雷公藤甲素单用及联合用药抗肿瘤的作用及机制研究进展[J].中国中药杂志，2019，44（16）：3391-3398.
|
| [11] |
阎玮兰.雷公藤甲素对MV411 细胞增殖抑制及在PI3KAKT-mTOR 通路机制研究[D].太原：山西医科大学，2017.
|
| [12] |
王昊，陈亮，叶小云.雷公藤甲素对TM4 细胞氧化应激及PI3K/AKT 通路的影响[J].北京大学学报（医学版），2018，50（4）：607-612.
|
| [13] |
白俊，吴也可，吴克明.雷公藤甲素通过PI3K/AKT/mTOR通路诱导卵巢颗粒细胞自噬的实验研究[J].中国中药杂志，2019，44（16）：3429-3434.
|
| [14] |
Bergerot P，Lamb P，Wang E.Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma：rationale and clinical evidence[J].Mol Cancer Ther，2019，18（12）：2185-2193.
|
| [15] |
Damayanti NP，Budka JA，Khella HWZ，et al.Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma[J].Clin Cancer Res，2018，24（23）：5977-5989.
|
| [16] |
Bodnar L，Stec R，Cierniak S，et al.Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines[J].Ann Oncol，2015，26（7）：1385-1389.
|
| [17] |
Ribback S，Cigliano A，Kroeger N，et al.PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men[J].Oncotarget，2015，6（15）：13 036-13 048.
|
| [18] |
Vlachostergios PJ.PI3K/AKT inhibitors in patients with refractory renal cell carcinoma：what have we learnt so far?[J].Ann Oncol，2017，28（5）：914-916.
|
| [24] |
胡志英，朱新江，陈舒晨，等.非小细胞肺癌PI3K/AKT/MTOR信号通路的研究现状与进展[J].癌症进展，2018，16（6）：671-674.
|
| [19] |
Corti F，Nichetti F，Raimondi A，et al.Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers：A review of current evidences and future perspectives[J].Cancer Treat Rev，2019，72（7）：45-55.
|
| [20] |
Barra F，Evangelisti G，Ferro Desideri L，et al.Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer[J].Expert Opin Investig Drugs，2019，28（2）：131-142.
|
| [21] |
Soleimani A，Rahmani F，Ferns GA，et al.Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer[J].Curr Pharm Des，2018，24（39）：4605-4610.
|
| [22] |
Corti F，Nichetti F，Raimondi A，et al.Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers：A review of current evidences and future perspectives[J].Cancer Treat Rev，2019，72（7）：45-55.
|
| [23] |
Khan MA，Jain VK，Rizwanullah M，et al.PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer：a review on drug discovery and future challenges[J].Drug Discov Today，2019，24（11）：2181-2191.
|
|
|
|
